Total Neoadjuvant Therapy for lymph node-positive adenocarcinoma of the OESophagus and oesophagogastric junction: a phase II, multicentre study. Studiecoördinator Dr. J.J. de Haan Afdeling Medische Oncologie Tel. : 050-3612821 (secretariaat Oncologie)...
Feasibility study of chemoradiation. TRAstuzumab and Pertuzumab in resectable HER2+ esophageal carcinoma: the TRAP study EudraCT nummer: 2013-004111-42 METc nummer: 2014.257 Onderzoekscode: Samenvatting Bij resectabele oesophaguscarcinomen en...
Dit is een open-label gerandomiseerde fase III studie waarbij standaardbehandeling volgens het CROSS- regime wordt vergeleken met CROSS + Trastuzumab en Pertuzumab. Eudractnummer: 2021-005328-39 Samenvatting Ongeveer 15% van...
A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician’s choice in patients with HER2-positive unresectable locally advanced or metastatic...
Vascular fingerprint to identify patients at risk for arterial cardiovascular events within the first year after start of cisplatin-based chemotherapy for testicular cancer: a validation study. METc nummer:...
Vaccination against cOvid In CancEr Protocol nummer: 202000865 METc nummer: 2020/588 Samenvatting Vaccinatie tegen het coronavirus is een standaardbehandeling en is onderdeel van het rijksvaccinatieprogramma. Binnen de VOICE...
Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin...
PRIMARY CHEMORADIATION VERSUS NEOADJUVANT CHEMOTHERAPY FOLLOWED BY SURGERY AS TREATMENT STRATEGY FOR LOCALLY ADVANCED VULVAR CARCINOMA (LVAC) Samenvatting De VULCANize2-studie is een studie waarbij patiënten met LAVC die...
Post-authorization safety study to evaluate the risks of myelodysplastic syndrome/acute myeloid leukemia and second primary malignancies in adult patients with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube,...
A phase II prospective imaging study evaluating the utility of pre-treatment zirconium-89 labelled trastuzumab PET/CT and an early FDG-PET/CT response to identify patients with advanced HER-2 positive breast...
